Gina Hong1, Kevin J Psoter2, Mark T Jennings3, Christian A Merlo3, Michael P Boyle4, Denis Hadjiliadis5, Steven M Kawut5, Noah Lechtzin3. 1. University of Pennsylvania Perelman School of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Philadelphia, PA, United States. Electronic address: gina.hong@uphs.upenn.edu. 2. Johns Hopkins School of Medicine, Department of Pediatrics, Division of General Pediatrics and Adolescent Medicine, Baltimore, MD, United States. 3. Johns Hopkins School of Medicine, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Baltimore, MD, United States. 4. Johns Hopkins School of Medicine, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Baltimore, MD, United States; Cystic Fibrosis Foundation, Bethesda, MD, United States. 5. University of Pennsylvania Perelman School of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Philadelphia, PA, United States.
Abstract
BACKGROUND: Aspergillus species are increasingly detected in the respiratory tracts of individuals with cystic fibrosis (CF), and chronic Aspergillus fumigatus is associated with more frequent hospitalizations for pulmonary exacerbations. However, patient and clinical factors that may contribute to the acquisition of persistent Aspergillus infection have yet to be identified. The objective of this study was to identify risk factors for development of Aspergillus respiratory isolation in CF. METHODS: A retrospective cohort study of participants in the CF Foundation Patient Registry between 2006 and 2012 was conducted. Generalized estimating equation models were used to evaluate the association between the development of persistent Aspergillus respiratory isolation and individual level demographic and clinical characteristics. RESULTS: Among 16,095 individuals with CF followed from 2006 to 2012, 1541 (9.6%) subjects developed persistent Aspergillus isolation. White race (Odds Ratio [OR] 1.74, 95% confidence interval 1.23, 2.48, p<0.001) and pancreatic insufficiency (OR 1.50, 95% CI 1.09, 2.06, p<0.001) were found to be risk factors for persistent Aspergillus isolation. Chronic therapies, including inhaled antibiotics (OR 1.33; 95% CI 1.21, 1.46), macrolides (OR 1.23, 95% CI 1.14, 1.32, p<0.001), and inhaled corticosteroids (OR 1.13, 95% CI 1.04, 1.20, p<0.001) were also independently associated with an increased risk for persistent Aspergillus isolation. CONCLUSIONS: We identified macrolides and inhaled antibiotics, which individually have been shown to improve CF outcomes, and inhaled corticosteroids as risk factors for developing persistent Aspergillus isolation. Further work is needed to determine whether these associations are causal or due to confounding by other factors.
BACKGROUND:Aspergillus species are increasingly detected in the respiratory tracts of individuals with cystic fibrosis (CF), and chronic Aspergillus fumigatus is associated with more frequent hospitalizations for pulmonary exacerbations. However, patient and clinical factors that may contribute to the acquisition of persistent Aspergillus infection have yet to be identified. The objective of this study was to identify risk factors for development of Aspergillus respiratory isolation in CF. METHODS: A retrospective cohort study of participants in the CF Foundation Patient Registry between 2006 and 2012 was conducted. Generalized estimating equation models were used to evaluate the association between the development of persistent Aspergillus respiratory isolation and individual level demographic and clinical characteristics. RESULTS: Among 16,095 individuals with CF followed from 2006 to 2012, 1541 (9.6%) subjects developed persistent Aspergillus isolation. White race (Odds Ratio [OR] 1.74, 95% confidence interval 1.23, 2.48, p<0.001) and pancreatic insufficiency (OR 1.50, 95% CI 1.09, 2.06, p<0.001) were found to be risk factors for persistent Aspergillus isolation. Chronic therapies, including inhaled antibiotics (OR 1.33; 95% CI 1.21, 1.46), macrolides (OR 1.23, 95% CI 1.14, 1.32, p<0.001), and inhaled corticosteroids (OR 1.13, 95% CI 1.04, 1.20, p<0.001) were also independently associated with an increased risk for persistent Aspergillus isolation. CONCLUSIONS: We identified macrolides and inhaled antibiotics, which individually have been shown to improve CF outcomes, and inhaled corticosteroids as risk factors for developing persistent Aspergillus isolation. Further work is needed to determine whether these associations are causal or due to confounding by other factors.
Authors: M Noni; A Katelari; G Dimopoulos; S-E Doudounakis; C Tzoumaka-Bakoula; V Spoulou Journal: Eur J Clin Microbiol Infect Dis Date: 2015-08-30 Impact factor: 3.267
Authors: Neelkamal Chaudhary; Kausik Datta; Frederic B Askin; Janet F Staab; Kieren A Marr Journal: Am J Respir Crit Care Med Date: 2011-12-01 Impact factor: 21.405
Authors: Bojana Mirković; Gillian M Lavelle; Ahmed Abdul Azim; Kristine Helma; Fatma S Gargoum; Kevin Molloy; Yael Gernez; Katie Dunne; Julie Renwick; Philip Murphy; Richard B Moss; Catherine M Greene; Cedric Gunaratnam; Sanjay H Chotirmall; Noel G McElvaney Journal: J Allergy Clin Immunol Date: 2015-09-18 Impact factor: 10.793
Authors: M Iversen; C M Burton; S Vand; L Skovfoged; J Carlsen; N Milman; C B Andersen; M Rasmussen; M Tvede Journal: Eur J Clin Microbiol Infect Dis Date: 2007-12 Impact factor: 3.267
Authors: Wan C Tsai; Michael L Rodriguez; Katherine S Young; Jane C Deng; Victor J Thannickal; Kazuhiro Tateda; Marc B Hershenson; Theodore J Standiford Journal: Am J Respir Crit Care Med Date: 2004-09-10 Impact factor: 21.405
Authors: Carsten Schwarz; Dominik Hartl; Olaf Eickmeier; Andreas Hector; Christian Benden; Isabelle Durieu; Amparo Sole; Silvia Gartner; Carlos E Milla; Peter James Barry Journal: Mycopathologia Date: 2017-07-31 Impact factor: 2.574
Authors: Caroline G Baxter; Riina Rautemaa; Andrew M Jones; A Kevin Webb; Matthew Bull; Eshwar Mahenthiralingam; David W Denning Journal: Thorax Date: 2013-03-19 Impact factor: 9.139
Authors: Bryan Coburn; Pauline W Wang; Julio Diaz Caballero; Shawn T Clark; Vijaya Brahma; Sylva Donaldson; Yu Zhang; Anu Surendra; Yunchen Gong; D Elizabeth Tullis; Yvonne C W Yau; Valerie J Waters; David M Hwang; David S Guttman Journal: Sci Rep Date: 2015-05-14 Impact factor: 4.379
Authors: Gina Hong; Kevin Alby; Sharon C W Ng; Victoria Fleck; Christina Kubrak; Ronald C Rubenstein; Daniel J Dorgan; Steven M Kawut; Denis Hadjiliadis Journal: J Cyst Fibros Date: 2019-08-21 Impact factor: 5.482
Authors: Axel Blomquist; Malin Inghammar; Mahasin Al Shakirchi; Petrea Ericson; Christina Krantz; Marcus Svedberg; Anders Lindblad; Lisa I Påhlman Journal: BMC Pulm Med Date: 2022-07-05 Impact factor: 3.320
Authors: Bumhee Yang; Taehee Kim; Jiin Ryu; Hye Yun Park; Bin Hwangbo; Sun-Young Kong; Yong-Soo Kwon; Seung Jun Lee; Seung Won Ra; Yeon-Mok Oh; Jang Won Sohn; Kang Hyeon Choe; Hayoung Choi; Hyun Lee Journal: J Pers Med Date: 2021-05-17